Lian X, Shen J, Gu Z, et al. - Researchers sought to review their experience in the treatment of pituitary somatotroph adenomas by fractionated intensity-modulated radiotherapy (IMRT), analyze the treatment outcomes and determine predictors. From August 2009 to January 2019, patients with pituitary somatotroph adenoma treated by IMRT in the institution were reviewed. In total, 113 patients (37 were male), median age 33 years (range 12-67 years), were involved in this investigation. One hundred twelve patients were not completely remission after surgery and 1 patient was treated with radiotherapy alone because she declined surgery. Data reported that the endocrine complete remission rates of IGF-1 at 1-, 2-, 3- and 5-years were 6%, 22.8%, 48.6% and 74.3%, respectively. It was noted that the median time to complete remission was 36.2 ± 3.8 months and the tumor control rate was 99% during the follow-up. The overall incidence of RT-induced hypopituitarism at the last follow-up was 28.3%. IMRT is a highly successful therapy for pituitary somatotroph adenoma. Endocrine remission rate, tumor control rate, the median remission time and incidence of hypopituitarism are comparable to SRS. Significant predictive factors in endocrine remission were age and IGF-1 level before radiotherapy.